Axsome Therapeutics (AXSM) Amortization of Deferred Charges (2015 - 2023)
Axsome Therapeutics (AXSM) reported Amortization of Deferred Charges of $314000.0 for Q1 2023, up 14.18% on a YoY basis from $275000.0 in Q1 2022, and down 3.24% sequentially from $324531.0 in Q4 2022.
Axsome Therapeutics (AXSM) Amortization of Deferred Charges (2015 - 2023) Analysis & Trends
Axsome Therapeutics (AXSM) has 5 years of Amortization of Deferred Charges data on file, last reported at $314000.0 in Q1 2023.
- For the quarter ending Q1 2023, Amortization of Deferred Charges rose 14.18% year-over-year to $314000.0; the trailing twelve-month figure through Mar 2023 stood at $1.2 million (up 9.98% YoY), and the FY2022 full-year result was $1.2 million, up 7.62% from the prior year.
- Amortization of Deferred Charges retreated to $314000.0 in Q1 2023, from $324531.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $324531.0 in Q4 2022 to a low of $262764.0 in Q1 2021.
- A 3-year average of $283868.7 and a median of $276364.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 17.43% in 2022, while the deepest fall reached 3.85% in 2022.
- Tracing AXSM's Amortization of Deferred Charges over 3 years: stood at $276364.0 in 2021, then increased by 17.43% to $324531.0 in 2022, then decreased by 3.24% to $314000.0 in 2023.
- Business Quant data shows AXSM's Amortization of Deferred Charges at $314000.0 in Q1 2023, $324531.0 in Q4 2022, and $283014.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 12.25 Bn | 11.95 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 314,000.00 |
| Mar 31, 2023 | 314,000.00 |
| Dec 31, 2022 | 324,531.00 |
| Dec 31, 2022 | 324,531.00 |
| Sep 30, 2022 | 283,014.00 |
| Sep 30, 2022 | 283,014.00 |
| Jun 30, 2022 | 278,960.00 |
| Jun 30, 2022 | 278,960.00 |
| Mar 31, 2022 | 275,000.00 |
| Mar 31, 2022 | 275,000.00 |
| Dec 31, 2021 | 276,364.00 |
| Dec 31, 2021 | 276,364.00 |
| Sep 30, 2021 | 272,512.00 |
| Sep 30, 2021 | 272,512.00 |
| Jun 30, 2021 | 267,673.00 |
| Jun 30, 2021 | 267,673.00 |
| Mar 31, 2021 | 262,764.00 |
| Mar 31, 2021 | 262,764.00 |
| Dec 31, 2017 | 85,628.00 |
| Dec 31, 2017 | 85,628.00 |